Pairing APOC3 or ANGPTL3 inhibitors with metabolic agents such as GLP-1/GIP receptor agonists may simultaneously address triglyceride burden, hepatic steatosis, pancreatitis risk, and cardiometabolic outcomes [56,57]. Here, APOC3 is linked to fatty liver disease.